Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies

World Journal of Surgical Oncology

Xiang He¹  Yuelong Zhang¹  Weiwen Yu¹  Mi Zhou¹  Shuai Wang¹  Jinjing He² 

[1] Department of Urology, Affiliated Zhejiang Provincial People’s Hospital, School of Medicine, Zhejiang University, Shangtang Road 158, Hangzhou 310014, Zhejiang Province, People’s Republic of China;Department of Ophthalmology, Affiliated Zhejiang Provincial People’s Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China

关键词: Serum concentration;    Observational studies;    Meta-analysis;    Prostate cancer;    Phytoestrogens;   

Others  :  1221423
DOI  :  10.1186/s12957-015-0648-9

 received in 2015-04-09, accepted in 2015-07-14,  发布年份 2015

【 摘 要 】

Background

Epidemiologic studies have reported various results relating phytoestrogens to prostate cancer (PCa). The aim of this study was to provide a comprehensive meta-analysis on the extent of the possible association between phytoestrogens (including consumption and serum concentration) and the risk of PCa.

Methods

Eligible studies were retrieved via both computer searches and review of references. The summary relative risk ratio (RR) or odds ratio (OR) and 95 % confidence interval (CI) were calculated with random effects models.

Results

A total of 11 studies (2 cohort and 9 case–control studies) on phytoestrogen intake and 8 studies on serum concentration were included in the meta-analysis. The pooled odds ratio (OR) showed a significant influence of the highest phytoestrogens consumption (OR 0.80, 95 % CI 0.70–0.91) and serum concentration (OR 0.83, 95 % CI 0.70–0.99) on the risk of PCa. In stratified analysis, high genistein and daidzein intake and increased serum concentration of enterolactone were associated with a significant reduced risk of PCa. However, no significant associations were observed for isoflavone intake, lignans intake, or serum concentrations of genistein, daidzein, or equol.

Conclusions

The overall current literature suggests that phytoestrogen intake is associated with a decreased risk of PCa, especially genistein and daidzein intake. Increased serum concentration of enterolactone was also associated with a significant reduced risk of PCa. Further efforts should be made to clarify the underlying biological mechanisms.

【 授权许可】

   
2015 He et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
• [2]Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon, France; 2010.
• [3]Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl. 2012; 14(3):365-74.
• [4]Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol. 2012; 35(5–6):362-9.
• [5]Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999; 70(3):439s-50.
• [6]Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al.. Vegetables, fruits, legumes and prostate cancer: a multiethnic case–control study. Cancer Epidemiol Biomarkers Prev. 2000; 9(8):795-804.
• [7]Yildiz F. Phytoestrogens in functional foods. CRC Press, Florida; 2005.
• [8]Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E. Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med. 2010; 235(1):90-7.
• [9]Azrad M, Vollmer RT, Madden J, Dewhirst M, Polascik TJ, Snyder DC et al.. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food. 2013; 16(4):357-60.
• [10]Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002; 132(12):3577-84.
• [11]Turner NJ, Thomson BM, Shaw IC. Bioactive isoflavones in functional foods: the importance of gut microflora on bioavailability. Nutr Rev. 2003; 61(6):204-13.
• [12]Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T et al.. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004; 34(2):86-9.
• [13]Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer. 2009; 61(5):598-606.
• [14]Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr. 2009; 89(4):1155-63.
• [15]Ganry O. Phytoestrogens and prostate cancer risk. Prev Med. 2005; 41(1):1-6.
• [16]Miller PE, Snyder DC. Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutr Clin Pract. 2012; 27(5):599-612.
• [17]DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88.
• [18]Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127(9):820-6.
• [19]Zintzaras E, Ioannidis J. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005; 28(2):123-37.
• [20]Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34.
• [21]Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-101.
• [22]Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63.
• [23]Hedelin M, Balter KA, Chang ET, Bellocco R, Klint A, Johansson JE et al.. Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate. 2006; 66(14):1512-20.
• [24]Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S et al.. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer. 2006; 56(1):31-9.
• [25]Hedelin M, Klint A, Chang ET, Bellocco R, Johansson JE, Andersson SO et al.. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Cancer Causes Control. 2006; 17(2):169-80.
• [26]Ward HA, Kuhnle GG, Mulligan AA, Lentjes MA, Luben RN, Khaw KT. Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database. Am J Clin Nutr. 2010; 91(2):440-8.
• [27]Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN, Multiethnic CS. Legume and isoflavone intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer. 2008; 123(4):927-32.
• [28]Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S et al.. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007; 16(3):538-45.
• [29]Bosetti C, Bravi F, Talamini R, Parpinel M, Gnagnarella P, Negri E et al.. Flavonoids and prostate cancer risk: a study in Italy. Nutr Cancer. 2006; 56(2):123-7.
• [30]Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003; 12(7):665-8.
• [31]Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, Goto K et al.. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007; 137(8):1974-9.
• [32]Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr. 2007; 98(2):388-96.
• [33]McCann SE, Ambrosone CB, Moysich KB, Brasure J, Marshall JR, Freudenheim JL et al.. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer. 2005; 53(1):33-41.
• [34]Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC et al.. Phytoestrogen intake and prostate cancer: a case–control study using a new database. Nutr Cancer. 1999; 33(1):20-5.
• [35]Lewis JE, Soler-Vila H, Clark PE, Kresty LA, Allen GO, Hu JJ. Intake of plant foods and associated nutrients in prostate cancer risk. Nutr Cancer. 2009; 61(2):216-24.
• [36]Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S. Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev. 2008; 17(10):2891-4.
• [37]Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G et al.. Circulating enterolactone and prostate cancer risk: a Nordic nested case–control study. Int J Cancer. 2002; 99(1):124-9.
• [38]Kilkkinen A, Virtamo J, Virtanen MJ, Adlercreutz H, Albanes D, Pietinen P. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 Pt 1):1209-12.
• [39]Stattin P, Bylund A, Biessy C, Kaaks R, Hallmans G, Adlercreutz H. Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Cancer Causes Control. 2004; 15(10):1095-102.
• [40]Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case–control study: the Japan Public Health Center. J Clin Oncol. 2008; 26(36):5923-9.
• [41]Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K et al.. Serum phytoestrogens and prostate cancer risk in a nested case–control study among Japanese men. Cancer Sci. 2004; 95(1):65-71.
• [42]Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K et al.. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2009; 100(11):1817-23.
• [43]Lampe JW. Emerging research on equol and cancer. J Nutr. 2010; 140(7):1369S-72.
• [44]Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr. 2004; 91(04):513-31.
• [45]Coward L, Barnes NC, Setchell KD, Barnes S. Genistein, daidzein, and their. beta.-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem. 1993; 41(11):1961-7.
• [46]Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. 1991.
• [47]Bhagwat S, Haytowitz DB, Holden JM. USDA database for the isoflavone content of selected foods release 2.0. US Department of Agriculture, Maryland; 2008.
• [48]Horn-Ross PL, Barnes S, Lee M, Coward L, Mandel JE, Koo J et al.. Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control. 2000; 11(4):289-98.
• [49]Akaza H. Prostate cancer chemoprevention by soy isoflavones: role of intestinal bacteria as the “second human genome”. Cancer Sci. 2012; 103(6):969-75.
• [50]Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer. 2000; 36(1):27-32.
• [51]Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK et al.. Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 2004; 64(3):510-5.
• [52]deVere WRW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 2010; 62(8):1036-43.
• [53]Kumar NB, Cantor A, Allen K, Riccardi D, Besterman‐Dahan K, Seigne J et al.. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004; 59(2):141-7.
• [54]Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D et al.. Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol. 2010; 8(1):3.
• [55]Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R et al.. A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 2007; 59(2):163-8.
• [56]Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H et al.. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer. 2011; 63(6):889-98.